O'Brien Greene & Co’s PLx Pharma Inc. Common Stock PLXP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-27,000
| Closed | – | – | 143 |
|
|
2025
Q2 | $0 | Hold |
27,000
| – | – | ﹤0.01% | 148 |
|
|
2025
Q1 | $0 | Hold |
27,000
| – | – | ﹤0.01% | 140 |
|
|
2024
Q4 | $0 | Hold |
27,000
| – | – | ﹤0.01% | 142 |
|
|
2024
Q3 | $0 | Hold |
27,000
| – | – | ﹤0.01% | 142 |
|
|
2024
Q2 | $0 | Hold |
27,000
| – | – | ﹤0.01% | 142 |
|
|
2024
Q1 | $0 | Hold |
27,000
| – | – | ﹤0.01% | 136 |
|
|
2023
Q4 | $0 | Hold |
27,000
| – | – | ﹤0.01% | 135 |
|
|
2023
Q3 | $0 | Buy |
27,000
+5,000
| +23% | – | ﹤0.01% | 130 |
|
|
2023
Q2 | $0 | Hold |
22,000
| – | – | ﹤0.01% | 127 |
|
|
2023
Q1 | $3K | Hold |
22,000
| – | – | ﹤0.01% | 123 |
|
|
2022
Q4 | $4K | Sell |
22,000
-45,020
| -67% | -$18.8K | ﹤0.01% | 126 |
|
|
2022
Q3 | $44K | Buy |
67,020
+44,680
| +200% | +$65.8K | 0.01% | 127 |
|
|
2022
Q2 | $54K | Sell |
22,340
-38,000
| -63% | -$106K | 0.02% | 127 |
|
|
2022
Q1 | $244K | Hold |
60,340
| – | – | 0.08% | 124 |
|
|
2021
Q4 | $483K | Sell |
60,340
-2,000
| -3% | -$23.4K | 0.16% | 90 |
|
|
2021
Q3 | $1.2M | Buy |
+62,340
| New | +$1.09M | 0.44% | 52 |
|
O'Brien Greene & Co's PLXP Position: Q3 2025 in Review
O'Brien Greene & Co sold out of PLx Pharma Inc. Common Stock (PLXP) in Q3 2025, closing a stake of 27,000 shares.
O'Brien Greene & Co first reported a position in PLXP in Q3 2021 and held it in 16 quarters. The position peaked at $1.2M in Q3 2021. 1 fund tracked by Wall St. Rank holds PLXP as of Q3 2025.
- O'Brien Greene & Co reported no remaining PLx Pharma Inc. Common Stock position as of Q3 2025 after selling out during the quarter.
- O'Brien Greene & Co sold 27,000 PLx Pharma Inc. Common Stock shares in Q3 2025.
- O'Brien Greene & Co first reported a position in PLx Pharma Inc. Common Stock in Q3 2021 and held it in 16 quarters.
- O'Brien Greene & Co's PLx Pharma Inc. Common Stock position peaked at $1.2M in Q3 2021.
- 1 fund tracked by Wall St. Rank held PLx Pharma Inc. Common Stock as of Q3 2025.
Based on O'Brien Greene & Co's 13F filing for Q3 2025, filed 10 Nov 2025.